Drug Approval | October 21, 2025
FDA approves Tezspire for chronic rhinosinusitis with nasal polyps
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
Subscribe To Our Newsletter & Stay Updated
